Close menu




January 29th, 2024 | 07:00 CET

Demo against the right, overtake the left with these stocks! PayPal, Saturn Oil + Gas, Evotec and Bayer

  • Mining
  • Oil
  • AI
  • Pharma
Photo credits: pixabay.com

Millions of people are on the streets, demonstrating for democracy. However, democracy also means pluralism, tolerance and fair discourse. It remains to be seen whether the politicians currently in power will eventually embrace these principles. The stock market is also a mass phenomenon, with many things developing in the same direction without much reflection. The herd instinct has both good and bad sides; on the capital markets, it often leads to irrational hype movements, as seen recently in the artificial intelligence sector. This technology is not an economic panacea either, as the elimination of jobs through the use of learning machines leads to less growth at the end of the day. As in all things, we need to use our heads, especially when it comes to the white knights of our future. Where are the opportunities for investors?

time to read: 4 minutes | Author: André Will-Laudien
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , Saturn Oil + Gas Inc. | CA80412L8832 , EVOTEC SE INH O.N. | DE0005664809 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
    "[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

    Full interview

     

    PayPal - Many promises, little innovation

    The American online payment service PayPal suffered a major setback in 2023, with its growth story stuttering in several places and investors ultimately abandoning the stock. Now, the management is going public and announcing promising news. However, with a renewed share price slump of 6% last week, the New Year offensive seems to have backfired.

    The much-anticipated Innovation Day failed to deliver new milestones, as some investors commented in forums. With a 33% online share of the US consumer landscape, the masses expected more than just a "cashback feature". Percentage rebates for reaching certain shopping thresholds are no longer a novelty, as retailers' bonus systems offer discounts in their online shops, providing consumers with many attractive coupons before their next purchase. Of course, one possible starting point is the use of AI to advance the world of personalized advertising.

    "We will set a new trend and now focus on the AI personalization of commerce," said CEO Alex Chriss in an interview. With more followers than trendsetters and clearly too little for the eager audience, the share was sold off further. A look at the Refinitiv Eikon rating platform shows 22 "Buy" recommendations out of a total of 46 ratings. The average price target is only a low USD 72.70, just 17% above the current price. Keep the stock on the watchlist until the price generates buy signals above the USD 70 mark. Before that, it lacks any attractiveness.

    Saturn Oil & Gas - Step by step into a new league

    The Canadian oil and gas specialist Saturn Oil & Gas continues to achieve great success with its new drilling techniques. The initial production results in the Cardium and Bakken light oil targets in southeastern Saskatchewan are impressive. With a 30-day average production (IP30) of approximately 233 barrels per day of light oil, the technical team is ahead of the Company's expected type curves for OHML Bakken wells in this area.

    "The strong initial production and low decline rates of the Viewfield 01-07 well are excellent indicators of the improved economics achieved through this new drilling innovation in the Canadian oil and gas sector. OHML wells require less surface space and less water compared to typical drilling and completion techniques used in the development of Bakken formations. The superior economics of OHML drilling provide access to light oil resources previously considered uneconomical and open up a broad new field for Saturn's future development," said Justin Kaufmann, Chief Development Officer.

    Saturn renegotiated its exploration credit facility in December. The amendment provided the Company with more financial flexibility to finalize its robust development plans for the fourth quarter of 2023. This allowed an additional OHML well to be drilled at the end of the year. With the new drilling locations, the output volume will increase; it stood at 26,265 barrels per day at the end of the third quarter and could develop above the 27,000 barrel mark in the first quarter. If the WTI price remains close to the USD 80 mark, an adjusted operating profit (Adj EBITDA) of around CAD 375 million is expected for 2023. Cash flow per share is estimated at CAD 2.25 per share, which is only slightly below the current market price of CAD 2.36. Saturn's low valuation continues to go unnoticed. Annual figures for 2023 will likely be published at the end of March, by which time the share price could already be above CAD 3.00. Collect up to CAD 2.50!

    Bayer and Evotec - Trading the technical rebound

    Bayer and Evoec shares are still struggling. The Leverkusen-based company has been under pressure for several years, with repeated operational setbacks and headwinds from the US lawsuits related to Monsanto's glyphosate. The takeover of the US CropScience giant caused the Bayer Group to lose a further USD 80 billion approximately in addition to the takeover price of USD 63 billion in 2016. Even worse than the billion-dollar hole of the Chrysler takeover by Daimler, this acquisition will go down in the record books of German M&A transactions with a value destruction of USD 140 billion. However, after a 5-year downward trend, Bayer may have reached an interesting level. The market capitalization is now only EUR 32 billion, with a consensus P/E ratio of 5.8 for 2024. In addition, there is a dividend of 6.4%. Risk-conscious investors are boldly moving in the EUR 31 to 33 range.

    The departure of the long-standing CEO, Dr. Werner Lanthaler, hit Evotec like a bomb. In addition to all the gloom, there are insider trading transactions dating back to 2021. These transactions were not properly reported via AdHoc and could now call BaFin, the German financial regulatory authority, into action. Hedge funds continue to impact the share price, while analysts see a buying opportunity in this non-operational issue. The Canadian bank RBC issues an "Outperform" rating with a price target of EUR 18.60, and Jefferies votes "Buy" with a 12-month price target of EUR 28. This represents an outright doubling from the current price level of EUR 14.25. Speculative investors are offering the shorties initial resistance here.

    While Bayer and PayPal remain in the red, Evotec has also entered a downward trend with the departure of its long-time CEO Lanthaler. Saturn Oil & Gas remains the only highlight. With an ever-increasing production output, its valuation is entering a new league. Source: Refinitiv Eikon from 26.01.2024

    The two indices, DAX 40 and NASDAQ100, are again up strongly in 2024. The IT and Artificial Intelligence sectors are setting the standard for excellent performance. PayPal, Bayer and Evotec are grappling with their specific challenges, while Saturn Oil & Gas consistently delivers better operational figures from one report to the next. With fundamental strength, a long-term breakout in the share price could be on the horizon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by André Will-Laudien on December 23rd, 2025 | 10:10 CET

    Top tips for 2026 – Critical metals and armaments! DroneShield, Pasinex, RENK, and Heidelberger Druck in focus

    • Mining
    • zinc
    • CriticalMetals
    • Defense
    • Drones
    • armaments

    In 2025, there was a pronounced rally in critical metals starting in the summer. This was largely triggered by China, which imposed export restrictions on rare metals and strategic raw materials in response to arbitrary tariff demands from the White House. The metal markets reacted with strong upward movements, and the procurement centers of Western industry reacted even more severely. In view of the needs of the near future, a large number of properties would have to be brought into production in the areas of copper, graphite, lithium, uranium, zinc, and rare earths. However, it takes around 10 years to set up a mine, including all permits and preliminary investigations. Because this is far too long for the current needs, the market is looking at projects that are about to start production or are already producing. We offer a few ideas from the supply chain and potential customers.

    Read

    Commented by Carsten Mainitz on December 23rd, 2025 | 08:45 CET

    USD 600 billion market potential – Pfizer and Bayer are in the race, Vidac Pharma in the fast lane?

    • Biotechnology
    • Biotech
    • Pharma

    The market for cancer drugs is the largest segment within the pharmaceutical industry and currently has a volume of over USD 200 billion. According to experts, the market will already be worth USD 500 to 600 billion by 2032 or 2033. Companies such as Pfizer and Bayer are among the industry leaders. As is often the case, however, there are promising stocks from the second and third tiers beyond the blue chips. One such company is Vidac Pharma. The Company is pursuing a new, promising approach to skin cancer. Analysts attest to the shares' great potential.

    Read

    Commented by Fabian Lorenz on December 23rd, 2025 | 07:35 CET

    Big news at the turn of the year! Nordex, Novo Nordisk, AJN Resources!

    • Mining
    • Gold
    • Commodities
    • renewableenergy
    • Biotechnology

    Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to continue participating in the gold bull market may therefore turn their attention to exploration companies. One such candidate is AJN Resources. The stock has already moved higher, yet still offers upside potential, supported by takeover speculation. Novo Nordisk has submitted an application for US approval following convincing Phase 3 results, a step that would be strategically significant for the Company. Meanwhile, Nordex remains one of the positive surprises of 2025, having reported another major order. The key question now is how far can the rally go?

    Read